LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Hospital Universitario La Fe
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario La Fe (21)
2024
-
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 2
2023
-
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
The Lancet Respiratory Medicine, Vol. 11, Núm. 1, pp. 74-86
-
First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations
Journal of Thoracic Oncology, Vol. 18, Núm. 2, pp. 204-222
-
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Journal for immunotherapy of cancer, Vol. 11, Núm. 2
-
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes
European Journal of Cancer, Vol. 183, pp. 174-187
-
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2063-2075
2022
-
RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer
Cancer, Vol. 128, Núm. 9, pp. 1801-1811
2021
-
Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273] (ESMO Open (2021) 6(5), (S2059702921002350), (10.1016/j.esmoop.2021.100273))
ESMO Open
-
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 2, pp. 198-211
-
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
ESMO Open, Vol. 6, Núm. 5
-
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888
-
Overview of virus and cancer relationships. Position paper
Revista Espanola de Quimioterapia, Vol. 34, Núm. 6, pp. 525-555
2019
-
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132
2018
-
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer
European Respiratory Journal
-
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell Lung Cancer (RELAY): Phase Ib Results
Clinical Lung Cancer, Vol. 19, Núm. 3, pp. 213-220.e4
2017
-
A consensus statement on the gender perspective in lung cancer
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 527-535
-
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 219-226
-
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non–Small-Cell Lung Cancer
Clinical Lung Cancer, Vol. 18, Núm. 1, pp. 96-99
2011
-
Brief report: Phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors
Oncology, Vol. 80, Núm. 3-4, pp. 219-222
2005
-
Risk-adapted management for patients with clinical stage I seminoma: The second Spanish Germ Cell Cancer Cooperative Group study
Journal of Clinical Oncology, Vol. 23, Núm. 34, pp. 8717-8723